Concepedia

Cost‐Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel

Emily S. Reese, C. Daniel Mullins, Amber L. Beitelshees, Eberechukwu Onukwugha

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2012 · 83 citations · 24 references

DOIFull text

Open access

Abstract

Genotype-guided antiplatelet therapy selection may be more cost-effective and may provide more clinical value due to fewer adverse outcomes.

References

24

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2007 · 6.7K citations · Full text

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

Jessica L. Mega, Sandra Close, Stephen D. Wiviott et al. · New England Journal of Medicine · 2008 · 2.4K citations · Full text

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

Tabassome Simon, Céline Verstuyft, Murielle Mary‐Krause et al. · New England Journal of Medicine · 2008 · 1.7K citations · Full text

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

Alan R. Shuldiner · JAMA · 2009 · 1.5K citations · Full text

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

Jean‐Philippe Collet, Jean‐Sébastien Hulot, Anna Pena et al. · The Lancet · 2008 · 964 citations

, , +14